


Georg Marckmann Institute of Ethics, History and Theory of Medicine

Ethical approaches to Innovation in Global Health

World Health Summit Satellite Event

"Innovation in Health: The contribution of biologic medicines to public health"

Berlin, October 10, 2016



Georg Marckmann





Explicit priority setting – Definition

- Explicit, *evidence based* determination what is more or less important in health care based on clearly defined *ethical criteria*
- Direct limited health care resources to those areas where they are *needed* most!
- Current situation in most health care systems
- *No explicit* priority setting
- But: *implicit* priorities "implemented" in the system by financing infrastructure, reimbursement of services, regulation of providers, market expectations, etc.
- ⇒ Often does not match primary health needs of the population!
- ⇒ Today: What role shall biologics play in the hc system?





Priority setting – distributive justice: 3 levels

Level	Area	Explanation
1	Allocation of research	Allocation of resources <i>into</i> biologics (vs. alternative ways to promote health, prevent and treat diseases)
2	resources	Allocation of resources <i>within</i> the field of biologics
3	Distribution of biologics	Distribution of / access to biologics





Priority setting – distributive justice: 3 levels

Level	Area	Explanation
1	Allocation of research	Allocation of resources <i>into</i> biologics (vs. alternative ways to promote health, prevent and treat diseases)
2	resources	Allocation of resources <i>within</i> the field of biologics
3	Distribution of biologics	Distribution of / access to biologics

Allocation of



Level 1: Allocation of resources *into* biologics (vs. other alternatives)

- Central issue: high investment in biologics ⇒ right priorities?
 - \Rightarrow Directed towards priority health needs of the population?
 - ⇒ Higher health gain if resources are invested in other approaches (including prevention)?
 - ⇒ Are existing *inequalities* in health status taken into account?
- Policy options:

LUDWIG-MAXIMILIANS-

UNIVERSITÄT MÜNCHEN

- (1) Explicit priority setting in public funding for research
 - Health care needs in an ageing society (chronic diseases, multi-morbidity)
 - Priority for disadvantaged (sub-)populations
 - Potential for improving health status in population
 - Priority for common diseases?
 - Cost-effectiveness (efficiency) anticipative assessment possible?
- (2) Incentives for pharmaceutical companies to invest in areas with high priority

Allocation of



Level 2: Resource allocation within biologics

- Investment in profitable areas ⇒ populations with rare (genetic) profile are neglected ⇒ "orphan populations"
- Neglect of vulnerable, already disadvantaged subpopulations
- Research with patient subgroups beyond biologics neglected ⇒ higher risks through insufficiently tested interventions

Policy options

LUDWIG-MAXIMILIANS-

UNIVERSITÄT

- Incentives for investments by pharmaceutical industry in "orphan populations" (cf. current orphan drug regulation)
- More public research funding in (genetically) rare patient populations
- Challenge: increasing number of "orphan drugs" ⇒ increasing public spending necessary ⇒ limits? priorities?





Priority setting – distributive justice: 3 levels

Level	Area	Explanation
1	Allocation of research resources	Allocation of resources <i>into</i> biologics (vs. alternative ways to promote health, prevent and treat diseases)
2		Allocation of resources <i>within</i> the field of biologics
3	Distribution of biologics	Distribution of / access to biologics





Challenge: many innovative biologicals are expensive

 \Rightarrow Affordability: Do public hc systems have to set limits? E.g. based on cost-effectiveness assessment (cf. the NHS)?

At the time of licensing of the drug: effectiveness/benefit under routine conditions difficult to assess

- Studies for licensing: usually assess efficacy under ideal conditions
- Selected, not representative samples
- Surrogate endpoints instead of patient relevant endpoints (\Rightarrow overall survival, quality of life)
- No head-to-head comparison with standard treatment ٠
- Incomplete data transparency (reporting & publication bias) ٠
- ⇒ Requirements for a needs oriented and fair allocation & distribution are often not met!



Distribution of biologics (2)



Policy options

(1) First: Improve effectiveness/benefit assessment

- Independent, publicly financed clinical studies after licensing of the drug (patient relevant outcomes)
- (Initially) coverage only in clinical studies ("coverage with evidence development")
- (Germany: benefit assessment according to AMNOG too early!)
- (2) Improve decision making on the micro level
 - Patients should be fully informed about benefits & risks of new treatments and alternatives (e.g. palliative care in advanced oncological disease)
 - Shared decisions making ⇒ respect patient preferences
- (3) Cost-effectiveness assessment (CEA/CUA)
 - Price negotiations with pharmaceutical industry
 - Consider limited coverage of interventions with bad incremental C/E-ratio
 - Goal: unlimited access to *real innovations* for all patients, exclusion of "pseudo innovations"



Thank you very much for your attention!

Slides: www.dermedizinethiker.de

Contact: <u>marckmann@lmu.de</u>





Procedural criteria	Substantive criteria
Transparency	Medical need
Justification	 severity of disease
Evidence-based	 urgency of treatment
Consistency	Expected individual benefit
Legitimacy	Cost-benefit ratio
Manage conflict of interest	
Revision & appeal	Meta criterion:
Regulation	 quality of evidence